Back

Non-targeted metabolomics identifies erythronate accumulation in cancer cells

Zhang, J.; Keibler, M. A.; Dong, W.; Ghelfi, J.; Cordes, T.; Kanashova, T.; Pailot, A.; Linster, C.; Dittmar, G.; Metallo, C. M.; Lautenschlaeger, T.; Hiller, K.; Stephanopoulos, G.

2022-12-04 biochemistry
10.1101/2022.12.04.519010 bioRxiv
Show abstract

Using a non-targeted isotope-assisted metabolomics approach, we identified erythronate as a metabolite that accumulates in several human cancer cell lines. Erythronate has been reported to be a detoxification product derived from off-target glycolytic metabolism. We provide data supporting a possible alternative route to erythronate production involving the dephosphorylation of the pentose phosphate pathway intermediate erythrose-4-phosphate to form erythrose, followed by the oxidation of erythrose by an aldehyde dehydrogenase. Finally, we detected increased erythronate concentrations in tumors relative to adjacent normal tissues from lung cancer patients. These findings suggest the accumulation of erythronate to be an example of metabolic reprogramming in cancer cells, raising the possibility that elevated level of erythronate may serve as a biomarker of certain types of cancer.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.